2023
Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysis
2015
Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials
Housri N, Khan AJ, Taunk N, Goyal S, Nelson CJ, Ferro A, Haffty BG. Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials. The Breast Journal 2015, 21: 387-394. PMID: 25919123, DOI: 10.1111/tbj.12419.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNon-white womenCancer patientsClinical trialsWhite womenRacial disparitiesRadiation oncology clinical trialsBreast cancer clinical trialsRetrospective cohort studyClinico-pathologic factorsLymph node positivityUse of chemotherapyClinical trial enrollmentOncology clinical trialsUse of brachytherapyBreast radiotherapy trialsCancer clinical trialsPaucity of dataCohort studyNode positivityPatient demographicsReceptor statusTrial enrollmentTumor characteristicsDisease stage